Atara Biotherapeutics Enters Agreement For Issuance And Sale Of Pre-Funded Warrants To Purchase 27,272,727 Shares Of Common Stock At $0.55 Per Pre-Funded Warrant Share In $15M Registered Direct Offering
Portfolio Pulse from Benzinga Newsdesk
Atara Biotherapeutics has entered into an agreement for the issuance and sale of pre-funded warrants to purchase 27,272,727 shares of its common stock. Each pre-funded warrant is priced at $0.55 per share in a registered direct offering.
January 08, 2024 | 2:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Atara Biotherapeutics is issuing pre-funded warrants for the purchase of over 27 million shares at $0.55 each, which may dilute current shareholders' equity.
The issuance of pre-funded warrants typically leads to dilution of existing shareholders' equity. This dilution often results in a negative short-term impact on the stock price as the market adjusts to the increased number of shares and potential downward pressure on the stock's value.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100